Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancer
Interventions: DRUG: inetetamab and PD-1 inhibitor combined with chemotherapy.
Sponsor: Henan Cancer Hospital